| Literature DB >> 35646793 |
Sergio Montero-Navarro1, Jesús Sánchez-Más2, Cristina Salar-Andreu1, Francisco Javier Molina-Payá1, Cristina Orts-Ruiz1, José Martin Botella-Rico1, José Tuells3, Noelia Rodríguez-Blanco1,4.
Abstract
Due to the COVID-19 pandemic, physical therapists have had to adopt a set of specific protection measures, which have had an impact on their clinical activity and economy. The objective was to evaluate the impact of the COVID-19 pandemic on the work of Spanish physical therapists, as well as their attitudes and predisposition to vaccination. An online questionnaire was divided into five sections: (1) demographic and professional data; (2) labor impact; (3) precautions and infection-control measures; (4) economic impact; and (5) vaccine acceptance and adverse effects. Of the 666 participants, 62.1% showed a reduction in their working hours motivated by: fear of infection (p = 0.007), financial issues (p = 0.002) and being in quarantine or isolation (p < 0.001). Of these, 36.4% were forced to close the clinic, 62.7% requested help from the government, but only 12.04% mentioned that it was adequate. The main prevention measures adopted were the use of gels and masks and, in the private sector, disinfection with ozone or ultraviolet light (p < 0.05). The acceptance of the vaccine was high, 87.5%, being lower among the group over 40 years of age, self-employed, widowed or separated. More adverse effects were mentioned after receiving the AstraZeneca-Oxford vaccine, compared to Pfizer-BioNTech or Moderna. In conclusion, this study assessed for the first time that the COVID-19 pandemic in Spain had a negative impact on work and finances of physical therapists. The vaccine was widely accepted, in part by the economic impact that an infection in the work setting could signify.Entities:
Keywords: COVID-19; SARS-CoV-2; acceptance; impact; physical therapists; vaccines
Mesh:
Year: 2022 PMID: 35646793 PMCID: PMC9133911 DOI: 10.3389/fpubh.2022.877232
Source DB: PubMed Journal: Front Public Health ISSN: 2296-2565
Demographic and professional data of the physical therapists (n = 666).
|
|
|
|---|---|
| Sex | |
| Female | 480 (72.1) |
| Male | 186 (27.9) |
| Age (years) | 32.8 ± 7.0 |
| Age group | |
| 20–29 years | 254 (38.1) |
| 30–39 years | 281 (42.2) |
| >40 years | 131 (19.7) |
| Marital status | |
| Single | 185 (27.8) |
| Married | 193 (29.0) |
| Living with a partner | 269 (40.4) |
| Divorced/Widowed | 19 (2.8) |
| Work experience (years) | 9.8 ± 6.9 |
| Group work experience | |
| <5 years | 190 (28.5) |
| 5–10 years | 192 (28.8) |
| 11–15 years | 138 (20.7) |
| >16 years | 146 (21.9) |
| Type of employment | |
| State / interim worker | 44 (6.6) |
| Freelancer | 324 (48.6) |
| Self-employed | 278 (41.7) |
| Sick leave /unemployed | 20 (3.0) |
| Professional role | |
| Employer | 101 (15.2) |
| Employee/freelancer | 556 (83.5) |
| No answer | 9 (1.4) |
Data shown as number of responses (percentage).
Figure 1Reasons provided by the physical therapists that resulted in the reduction of scheduled appointments during the pandemic.
Personal protection equipment, hygiene measures, and safety measures incorporated at work during the pandemic by the physical therapists.
|
|
|
|
|
| |
|---|---|---|---|---|---|
|
| |||||
| FFP2 or FFP3 masks | 599 (92.7) | 557 (92.5) | 42 (95.5) | 0.52 | 0.470 |
| Surgical masks | 425 (65.8) | 396 (65.8) | 29 (65.9) | <0.01 | 0.986 |
| Gloves | 418 (64.7) | 393 (65.3) | 25 (56.8) | 1.29 | 0.257 |
| Goggles or protection screens | 368 (57.0) | 343 (57.0) | 25 (56.8) | <0.01 | 0.984 |
| Disposable gown | 276 (42.7) | 259 (43.0) | 17 (38.6) | 0.32 | 0.570 |
| Disposable shoe covers | 113 (17.5) | 105 (17.4) | 8 (18.2) | 0.02 | 0.901 |
| Disposable caps | 103 (15.9) | 92 (15.3) | 11 (25.0) | 2.89 | 0.089 |
|
| |||||
| Water-alcohol gels | 618 (95.7) | 577 (95.8) | 41 (93.2) | 0.70 | 0.402 |
| Time between patients | 478 (74.0) | 446 (74.1) | 32 (72.7) | 0.04 | 0.843 |
| Not seeing two patients at the same time | 264 (40.9) | 247 (41.0) | 17 (38.6) | 0.10 | 0.755 |
| Ventilation and disinfection of the rooms | 253 (39.2) | 237 (39.4) | 16 (36.4) | 0.16 | 0.693 |
| Air filtration equipment | 151 (23.4) | 143 (23.8) | 8 (18.2) | 0.71 | 0.399 |
| PCR test of oneself | 67 (10.4) | 67 (11.1) | 0 (0.0) | 5.46 | 0.019 |
| Company provides PCR test | 78 (12.1) | 75 (12.5) | 3 (6.8) | 1.23 | 0.268 |
| Disinfection with ozone | 61 (9.4) | 61 (10.1) | 0 (0.0) | 4.92 | 0.026 |
| Ultraviolet light | 21 (3.3) | 21 (3.5) | 0 (0.0) | 4.34 | 0.046 |
Data shown as n (%).
p <0.05 Chi square calculated as contingency table.
Population calculated after eliminating those who were sick leave or unemployed (n = 646).
Impact of COVID-19, vaccine acceptance and adverse effects of vaccination.
|
|
|
|---|---|
| Have you been infected with COVID-19? | |
| Yes | 103 (15.5) |
| Were you quarantined? | |
| Yes | 219 (32.9) |
| Have you received the COVID-19 vaccine? | |
| No | 85(12.8) |
| Rejected | 35 (5.3) |
| It was not offered to me | 50 (7.5) |
| Yes | 581 (87.2) |
| What vaccine was used as the first dose? ( | |
| AZ | 406 (61.0) |
| PB | 141 (21.2) |
| Mo | 34 (5.1) |
| Did you receive a second dose? Which one ( | |
| No | 221 (38.0) |
| Waiting | 136 (61.5) |
| It was not offered to me | 50 (22.6) |
| Rejected | 35 (15.8) |
| Yes | 445 (62.0) |
| AZ | 259 (58.2) |
| PB | 161 (36.2) |
| Mo | 25 (5.6) |
| Any adverse effects after vaccination? ( | |
| Yes | 528 (90.9) |
| Pain in the arm | 471 (81.1) |
| Tiredness | 365 (62.8) |
| Fever | 290 (49.9) |
| Headache | 274 (47.2) |
| Generalized muscle pain | 268 (46.1) |
| Shivering | 245 (42.2) |
| Inflammation of the ganglia | 47 (8.1) |
| Vomiting | 31 (5.3) |
| Would you accept a second dose? ( | |
| Yes, even if it's a different brand | 28 (24.3) |
| Yes, but only if it's the same brand | 80 (69.6) |
| No, under no circumstances | 4 (3.5) |
| I don't know | 3 (2.6) |
Data shown as n (%).
percentage calculated with respect to the total number of participants who received the first AZ dose and were waiting to receive the second one. AZ, AstraZeneca-Oxford; PB, Pfizer-BioNTech; Mo, Moderna.
Multivariate logistic regression analyses showing adverse effects associated to the vaccine brand received by the physical therapists who participated in the study.
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| Pain at the place where the vaccine was administered | |||||||
| Yes | 330 (81.3) | 112 (79.4) | 1.61 (0.77–3.36) | 0.203 | 29 (85.3) | 0.93 (0.30–2.90) | 0.894 |
| Fever | |||||||
| Yes | 231 (56.9) | 44 (31.2) | 0.67 (0.40–1.13) | 0.132 | 15 (44.1) | 1.43 (0.60–3.40) | 0.421 |
| Headache | |||||||
| Yes | 219 (53.9) | 42 (29.8) | 0.49 (0.31–0.77) | 0.002 | 13 (38.2) | 0.69 (0.32–1.50) | 0.351 |
| Vomiting | |||||||
| Yes | 28 (6.9) | 2 (1.4) | 0.48 (0.11–2.13) | 0.332 | 1 (2.9) | 1.22 (0.14–10.5) | 0.858 |
| Tiredness | |||||||
| Yes | 264 (65.0) | 82 (58.2) | 1.48 (0.89–2.44) | 0.129 | 18 (52.9) | 0.92 (0.42–2.05) | 0.844 |
| Shivering | |||||||
| Yes | 208 (51.2) | 29 (20.6) | 0.34 (0.20–0.58) | <0.001 | 8 (23.5) | 0.32 (0.12–0.82) | 0.017 |
| Generalized muscle pain | |||||||
| Yes | 212 (52.2) | 50 (35.5) | 0.90 (0.54–1.49) | 0.678 | 6 (17.6) | 0.23 (0.08–0.62) | 0.004 |
| Inflammation of the ganglia | |||||||
| Yes | 36 (8.9) | 6 (4.3) | 0.56 (0.22–1.44) | 0.229 | 5 (14.7) | 0.12 (0.01–1.22) | 0.353 |
Data shown as n (percent within the vaccine brand). OR = calculated for each answer as compared to all the others; p = calculated for the Chi-square test group. The negative response to the presence of the adverse effect was taken as the reference value for the multivariate logistic regression analysis. AZ, AstraZeneca-Oxford; PB, Pfizer-BioNTech. Mo, Moderna.
p <0.05 Chi-square calculated as contingency table.
Profile of the physical therapist who accepts or rejects the COVID-19 vaccine.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| Sex | 0.30 | 0.586 | |||
| Female | 447 (72.6) | 423 (94.6) | 24 (5.4) | ||
| Male | 169 (27.4) | 158 (93.5) | 11 (6.5) | ||
| Age group | 10.14 | 0.006 | |||
| 20–29 years | 230 (37.3) | 223 (97.0) | 7 (3.0) | ||
| 30–39 years | 261 (42.4) | 247 (94.6) | 14 (5.4) | ||
| >40 years | 125 (20.3) | 111 (88.8) | 14 (11.2) | ||
| Marital status | |||||
| Single | 166 (29.6) | 161 (97.0) | 5 (3.0) | 27.76 | <0.001 |
| Married | 177 (28.7) | 164 (92.7) | 13 (7.3) | ||
| In couple | 254 (41.2) | 243 (95.7) | 11 (4.3) | ||
| Divorced/Widowed | 19 (3.1) | 13 (68.4) | 6 (31.6) | ||
| Group work experience | 4.89 | 0.180 | |||
| <5 years | 171 (27.8) | 163 (95.3 | 8 (4.7) | ||
| 5–10 years | 178 (28.9) | 192 (28.8) | 192 (28.8) | ||
| 11–15 years | 130 (21.1) | 121 (93.1) | 9 (6.9) | ||
| >16 years | 137 (22.2) | 125 (91.2) | 12 (34.3) | ||
| Type of employment | |||||
| State / interim | 44 (7.1) | 40 (90.9) | 4 (9.1) | 8.55 | 0.036 |
| Freelancer | 294 (47.7) | 272 (92.5) | 22 (7.5) | ||
| Self-employed | 262 (42.5) | 255 (97.3) | 7 (2.7) | ||
| Not actives | 16 (2.6) | 14 (87.5) | 2 (12.5) | ||
| Professional role | |||||
| Employer | 511 (83.0) | 90 (92.8) | 26 (5.1) | 0.72 | 0.396 |
| Employee/freelancer | 97 (15.7) | 485 (94.9) | 7 (7.2) | ||
| No answer | 8 (1.3) |
Data shown as number of responses (percentage).
p < 0.05 Chi-square calculated as contingency table.
Figure 2Reasons provided for COVID-19 vaccine acceptance.